Intensity Therapeutics, Inc.
corporate_fare Company Profile
Intensity Therapeutics, Inc. (NASDAQ:INTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for INTS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for INTS spans 10-Q, 8-K, 10-K, 424B5.
Recent high-impact activity:
- Q3 Loss Widens to $3.5M as Cash Drops to $8.5M; Two Trials Resume Enrollment
- Intensity Therapeutics Q3 2026: Cash Falls to $8.5M, Going-Concern Doubt Persists
- Intensity Therapeutics Restarts Key Cancer Trials, Cash at $9.5M
- Intensity Therapeutics Q2 2026: Cash Drops to $9.5M, Going Concern Warning Reiterated, Clinical Trials Resume
- Stockholders Approve 6.6% Potential Dilution for Incentive Plans
Financial Snapshot
Short Interest & Short Volume
7.24 days to coverFINRA reported short interest of 75,853 shares in INTS as of the October 30, 2026 settlement, a 13.6% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 20, 2026, 28.7% of INTS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for INTS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-16.
Increased Share Authorization · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →